Fresh concerns have been raised about an increased risk of acute MI in patients who are taking dabigatran or rivaroxaban for atrial fibrillation, claim researchers involved in a large retrospective study that has revisited the issue. However, speaking to the limbic cardiologists say the findings most likely reflect the confounding nature of ‘real-world’ studies. Current ...
Australian cardiologists pour cold water on latest DOAC safety data
By Sunalie Silva
31 Mar 2017